Oncologist最新文献

{"title":"Analysis of outcomes according to start timing of adjuvant chemotherapy in patients with gastric cancer: a retrospective nationwide cohort study.","authors":"Tae-Hwan Kim, Eunyoung Lee, Hyun Woo Lee, Mi Sun Ahn, Yong Won Choi, Minsuk Kwon, Seok Yun Kang, Bumhee Park, Jin-Hyuk Choi","doi":"10.1093/oncolo/oyaf132","DOIUrl":"10.1093/oncolo/oyaf132","url":null,"abstract":"<p><strong>Background: </strong>Gastrectomy with D2 lymph node dissection followed by adjuvant chemotherapy (AC) with S-1 or capecitabine/oxaliplatin (CAPOX) is the standard treatment for stage II and III gastric cancer (GC). However, there is no established guideline for the start timing of AC.</p><p><strong>Methods: </strong>We analyzed data from the Korean Health Insurance Review and Assessment Service on 19 140 GC patients who received AC with S-1 (n = 10 442) or CAPOX (n = 8698) between January 2014 and December 2018. Patients were categorized based on AC initiation timing: within 6 weeks (n = 12 843), 6-8 weeks (n = 5386), and >8-16 weeks (n = 911).</p><p><strong>Results: </strong>Initiating AC within 6 weeks significantly improved 5-year disease-free survival (DFS) and overall survival (OS) compared to later initiation, with consistent findings across both S-1 and CAPOX groups (all P < .005). These associations remained significant in multivariable analysis and after propensity score matching (all P < .0001). However, this nationwide big-data analysis has limitations, including potential survival status misclassification and the absence of some important variables such as pathologic stage, performance status, and postoperative complications.</p><p><strong>Conclusion: </strong>To optimize outcomes, AC for GC should be initiated within 6 weeks after gastrectomy, provided patients have fully recovered.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":"30 6","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12160814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor in response to the article: \"Squamous cell carcinoma arising in chronically damaged skin (Marjolijn's Ulcer)\".","authors":"Zvi Ackerman","doi":"10.1093/oncolo/oyaf160","DOIUrl":"10.1093/oncolo/oyaf160","url":null,"abstract":"","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12199250/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144174558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In reply to: \"Letter to the editor in response to the article:'Squamous cell carcinoma arising in chronically damaged skin (Marjolijn's Ulcer)'\".","authors":"Mor Miodovnik, Yardenna Dolev, Roni Buchen, Miriam Rivka Brezis, Alla Nikolaevski-Berlin, Inbar Finkel, Ido Wolf, Inna Ospovat, Orit Gutfeld, Yasmin Leshem","doi":"10.1093/oncolo/oyaf161","DOIUrl":"10.1093/oncolo/oyaf161","url":null,"abstract":"","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12199246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144259331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prolonged response to PIK3CA inhibition in an advanced hormone-positive breast cancer patient with 3 mutations in the alpha subunit of PI-3 kinase.","authors":"Rotem Merose, Raya Leibowitz","doi":"10.1093/oncolo/oyaf126","DOIUrl":"10.1093/oncolo/oyaf126","url":null,"abstract":"<p><p>Mutations in the oncogene PIK3CA are implicated in many types of solid tumors and are prevalent in estrogen-receptor (ER)-positive Her2-negative (ER+Her2-) breast cancer (BC). In recent years, a combination of a drug-modulating ER and a PIK3CA inhibitor was approved for PIK3CA-mutant BC. We present a case of a 69-year-old otherwise healthy woman who was diagnosed with early ER+Her2- BC at the age of 47 and was treated with lumpectomy, adjuvant chemotherapy, radiation, and adjuvant tamoxifen. Five years after the termination of chemotherapy, she was diagnosed with bone metastasis and received several lines of endocrine therapy and subsequent capecitabine for 17 years altogether. Upon disease progression in the liver and lung, a \"liquid biopsy\" from the blood detected 3 missense mutations in PIK3CA, one of which was known to be deleterious (H1047R). The patient started a combination of Fulvestrant and Alpelisib with a deep and prolonged clinical and radiological response for 3 years. The occurrence of multiple mutations in PIK3CA was documented in 12-15% of BCs. A retrospective analysis showed that ER+Her2- BC patients with multiple PIK3CA mutations had a significantly higher response rate to PIK3CA inhibitor. It is impossible to determine whether our patient's extremely prolonged progression-free survival on Alpelisib-Fulvestrant was a result of the multiplicity of mutations in PIK3CA, the existence of the known deleterious mutation H1047R, or other clinical/biological factors. Our case highlights the potential importance of the number of PIK3CA mutations observed in a pathological sample or liquid biopsy, despite it being still unknown how to incorporate the multiplicity or singularity of PIK3CA mutations into clinical decision-making.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":"30 6","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12204390/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144327760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-in-human phase I/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer.","authors":"Ryan J Sullivan, Oladapo O Yeku, Deanna Teoh, Shilpa Gupta, Daniela Matei, Andressa S Laino, Jing Sun, Lili Zhu, Linh Van, Stephanie Pascarella, Sima J Zacharek, Khanh T Do, Antonio Jimeno","doi":"10.1093/oncolo/oyaf115","DOIUrl":"10.1093/oncolo/oyaf115","url":null,"abstract":"<p><strong>Background: </strong>mRNA-2416 is a novel lipid nanoparticle-encapsulated messenger RNA (mRNA) encoding human OX40 ligand (OX40L) for intratumoral (Itu) injection. OX40L plus immune checkpoint inhibitor (ICI) increased preclinical antitumor activity, thus mRNA-2416 plus ICI may potentiate antitumor activity.</p><p><strong>Methods: </strong>This first-in-human, phase I/II, open-label, multicenter study examined the safety, tolerability, and efficacy of mRNA-2416 alone (arm A) or with durvalumab (arm B) in patients with advanced solid tumors or lymphoma (NCT03323398). Phase I primary objectives included assessment of safety/tolerability and maximum tolerated dose (MTD)/recommended dose for expansion; phase II arm B dose expansion assessed objective response rate in ovarian cancers. Secondary objectives included pharmacokinetics, disease control rate, duration of response, and progression-free survival (PFS). Assessments of immunologic response to treatment were exploratory.</p><p><strong>Results: </strong>From August 2017 to August 2021, 79 patients were enrolled; 61 received treatment (arm A: 39, arm B: 22), including 16 in the expansion cohort. MTD was not reached. Treatment-related emergent adverse events were primarily grade 1/2, with 8 grade 3 and no grade 4/5 events. On-treatment tumor biopsies demonstrated increased OX40L protein expression, elevated PD-L1, and proinflammatory responses. Tumor shrinkage occurred in injected and surrounding non-injected tumors. Median (95% CI) PFS was 60.0 (50.0 to 108.0) and 50.0 (38.0 to 55.0) days for arms A and B, respectively.</p><p><strong>Conclusions: </strong>mRNA-2416 alone or with durvalumab was well tolerated. Pharmacodynamic analyses support Itu mRNA proof-of-concept. Predefined primary efficacy endpoints were not met in an exploratory cohort of ovarian cancer. Additional research is warranted to further inform this therapeutic approach.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":"30 6","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12166121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Qualitative study of patient and caregiver experiences during multimodality treatment for locally advanced rectal cancer.","authors":"Kelsey S Lau-Min, Riley Psenka, Mia Holtze, Katina Massad, Andrea Hansen, Stephen B Lo, Areej El-Jawahri, Jennifer S Temel, Aparna Parikh, Ryan Nipp, Lara Traeger","doi":"10.1093/oncolo/oyaf128","DOIUrl":"10.1093/oncolo/oyaf128","url":null,"abstract":"<p><strong>Background: </strong>Locally advanced rectal cancer (LARC) is treated with combined chemotherapy, radiation, and surgery to maximize the potential for cure. This multimodality treatment approach can result in substantial toxicity for patients, including life-altering changes in bowel, urinary, and sexual function as well as decrements in quality of life (QOL). We explored the lived experiences of patients and caregivers during multimodality treatment for LARC.</p><p><strong>Methods: </strong>We conducted a qualitative study of patients undergoing multimodality treatment for LARC and their designated caregivers. Each participant completed an hour-long individual in-depth interview using a semistructured interview guide covering treatment experiences, coping strategies, and supportive care needs. We transcribed, coded, and analyzed interviews using a thematic analysis approach and constant comparison methods.</p><p><strong>Results: </strong>We included 21 patients (median age 51 years, 11 women, 17 white, 10 post-surgical resection) and 10 caregivers (6 married/living with patients). We identified five themes among patients and caregivers: (1) the lengthy, complex, and unpredictable nature of multimodality therapy; (2) need to balance receiving detailed information with avoiding information overload; (3) the profound impact that multimodality therapy had on multiple QOL domains; (4) use of coping mechanisms to maintain control and preserve identity; and (5) desire for additional informational and supportive care resources.</p><p><strong>Conclusion: </strong>Patients and caregivers face important challenges in navigating care for LARC due to the complicated and unpredictable nature of multimodality therapy. Findings from this study should inform the development of interventions to address the immense informational and supportive care needs of patients receiving multimodality treatment for LARC.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":"30 6","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12135775/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144217543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic value of sarcopenia and sarcopenic obesity in patients with lung cancer receiving immunotherapy: a propensity score matching study.","authors":"Wen Wang, Xintian Xu, Hongming Liu, Yongxia Cui, Qian Han, Tingting Yang, Mengxing Tian, Yu Qian, Xin Jin, Lei Lei","doi":"10.1093/oncolo/oyaf114","DOIUrl":"10.1093/oncolo/oyaf114","url":null,"abstract":"<p><strong>Background: </strong>Sarcopenic obesity (SO) is a prognostic factor and its impact on response to immunotherapy is still unknown in lung cancer. We aimed to explore the role of SO and body composition in predicting overall survival (OS) in patients with lung cancer receiving immune checkpoint inhibitors (ICIs).</p><p><strong>Methods: </strong>We conducted a retrospective study involving 119 patients with lung cancer who underwent immunotherapy. The subcutaneous fat area (SFA), visceral fat area (VFA) and skeletal muscle index (SMI) were determined by the cross-sectional computed tomography at the L3 lumbar vertebral level. Sarcopenia and SO were defined by SMI and body mass index. Kaplan-Meier and Cox proportional hazard analyses were used to evaluate the impact of body composition on survival. The propensity score matching (PSM) analysis was used to reduce bias and a nomogram was created to predict the OS.</p><p><strong>Results: </strong>The Kaplan-Meier survival showed that patients with sarcopenia and SO had poor survival time in the total and PSM cohort. The Cox analyses revealed that sarcopenia (Hazard ratio (HR): 2.04, 95% Confidence Interval (CI): 1.04-4.01, P = 0.039) and SO (HR: 3.17, 95%CI: 1.49-6.75, P = 0.003) were independent OS predictors. SFA and VFA were not associated with OS. The SMI, age, stage, albumin level and SFA were used to develop a nomogram. Patients with high nomogram scores had worse OS (P < 0.0001).</p><p><strong>Conclusions: </strong>Sarcopenia and SO are prognostic factors in patients with lung cancer receiving ICIs. A nomogram that integrates body composition is sufficiently accurate for predicting OS in patients with lung cancer receiving immunotherapy.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":"30 6","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12205993/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcome and deep learning imaging characteristics of patients treated by radio-chemotherapy for a \"molecular\" glioblastoma.","authors":"Caroline Zerbib, Lucas Robinet, Soleakhena Ken, Ana Cavillon, Margaux Roques, Delphine Larrieu, Aurore Siegfried, Franck Emmanuel Roux, Ahmad Berjaoui, Elizabeth Cohen-Jonathan Moyal","doi":"10.1093/oncolo/oyaf127","DOIUrl":"10.1093/oncolo/oyaf127","url":null,"abstract":"<p><strong>Background: </strong>Since 2021, glioblastomas have been classified into two subgroups: classic glioblastomas (histGB), defined as IDH wild-type grade 4 astrocytomas with necrosis and vascular proliferation, showing contrast enhancement (CE) on MRI; and molecular glioblastomas (molGB), characterized by specific alterations (7+/10-, EGFR amplification, TERT mutation). Although not always the case, molGB often lack CE and may mimic low-grade gliomas (LGG), hence complicating the diagnosis. Survival outcomes remain debated. This study aimed to evaluate the response of molGB to standard treatment and assess the ability of machine learning and deep learning to differentiate molGB without CE from LGG on MRI.</p><p><strong>Methods: </strong>We retrospectively studied 132 glioblastoma patients treated with radiotherapy and temozolomide, comparing the survival outcomes of histGB and molGB. Artificial intelligence (AI) models were trained using features from MRI FLAIR hypersignal segmentation to distinguish molGB without CE from LGG.</p><p><strong>Results: </strong>No significant difference in median overall survival (OS) (20.6 vs 18.4 months, P = .2) or progression-free survival (10.1 vs 9.3 months, P = .183) was observed between molGB and histGB. However, molGB without CE demonstrated improved median OS (31.2 vs 18 months, hazard ratios 0.45). Artificial intelligence models distinguished molGB without CE from LGG, achieving a best-performing ROC AUC of 0.85.</p><p><strong>Conclusions: </strong>While patients with molGB and histGB have similar overall survival, patients with molGB without CE appear to have better outcomes. Artificial intelligence models effectively differentiate molGB from LGG, supporting their potential diagnostic utility.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":"30 6","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12204753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The predictive value of serial troponin measurements in patients treated with immune checkpoint inhibitors.","authors":"Moran Gvili Perelman, Rafael Y Brzezinski, Barliz Waissengrin, Yasmin Leshem, Ari Raphael, Maxim Perelman, Noam Weiss, Maor Tzuberi, Moshe Stark, Ilana Goldiner, Shafik Khoury, Ofer Havakuk, Yan Topilsky, Shmuel Banai, Rabea Asleh, Ido Wolf, Michal Laufer-Perl","doi":"10.1093/oncolo/oyaf147","DOIUrl":"10.1093/oncolo/oyaf147","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) may lead to immune-related adverse events, including potentially life-threatening cardiovascular (CV) complications. Despite guideline-recommended troponin monitoring, limited data exist on evaluating its predictive significance.</p><p><strong>Objective: </strong>We aimed to assess the predictive value of serial high-sensitivity troponin I (hs-TnI) monitoring in patients treated with ICIs.</p><p><strong>Methods: </strong>A retrospective, single-center, observational study including patients treated with ICIs and performing serial hs-TnI measurements. The primary endpoint was all-cause mortality, and the secondary endpoint was CV events, defined as the composite of myocarditis, pericarditis, acute coronary syndrome, heart failure, or arrhythmias. A tree classifier model identified the most predictive hs-TnI concentration for the main study endpoints.</p><p><strong>Results: </strong>Overall, 455 patients performed baseline (T1) and follow-up hs-TnI (T2) assessments and were included in the cohort. During a mean follow-up of 25 months (IQR [12-36]), 253 (56%) patients died, and 70 (15%) developed CV events. T2 > 8 ng/L was significantly associated with increased all-cause mortality (64% vs 48%, P < .001) and CV events (22% vs 9%, P < .001), notably HF (12% vs 4%, P = .003) and myocarditis (3% vs 0%, P = .038). A multivariable analysis confirmed that T2 > 8 ng/L was an independent predictor for all-cause mortality (HR 1.67, 95% CI: 1.29-2.17, P < .001) and CV events (HR 2.59, 95% CI: 1.50-4.46, P = .001).</p><p><strong>Conclusions: </strong>Our study emphasizes the significant role of serial troponin monitoring during ICIs therapy as an independent predictor of all-cause mortality and CV events, and suggests an optimal lower hs-TnI cutoff of >8 ng/L for risk stratification. Large prospective trials are needed to confirm these findings.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":"30 6","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12205246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144531154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of sociodemographic determinants on enrollment into contemporary lymphoma clinical trials: a systematic review.","authors":"Jun Yang Jiang, Ang Li, Alexis Romero, Christopher R Flowers, Chijioke Nze","doi":"10.1093/oncolo/oyaf180","DOIUrl":"10.1093/oncolo/oyaf180","url":null,"abstract":"<p><p>While the incidence and survival associated with lymphoma have improved in recent years, outcome disparities related to sociodemographic factors such as age, sex, race, ethnicity, socioeconomic status (SES), and other social determinants of health (SDOH) remain prevalent in the modern era. Clinical trials are crucial for further improving outcomes, yet not all sociodemographic groups are equally represented in contemporary lymphoma trials. We conducted a systematic review of the literature evaluating the impact of SDOH on enrollment into clinical trials in the United States and identified 21 relevant studies. We confirmed that Black and Hispanic individuals are underrepresented in lymphoma clinical trials, due largely to the geographic distribution of clinical trial sites and exacerbated by globalization of cancer trials. Women may also be less appropriately represented than men, although this association is less robust and consistent. Adolescents and young adults with lymphoma who are older, treated at adult cancer centers, or managed by adult hematologists/oncologists are all less likely to be part of trials. Older adults are also excluded from most lymphoma clinical trials. There is a dearth of data on how other SDOHs including education, employment, and household income contribute to differences in clinical trial enrollment. Further research is required to explore the intersection of demographics, SES, insurance status, and enrollment into lymphoma clinical trials.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12207873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144487172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}